BMS Files For Approval Of Melanoma Drug Ipilimumab In Japan
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb has filed for the approval of ipilimumab for the treatment of unresectable or metastatic malignant melanoma in Japan.